RT Journal Article
SR Electronic
T1 Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment
JF Cancer Genomics - Proteomics
JO Cancer Genomics Proteomics
FD International Institute of Anticancer Research
SP 531
OP 541
DO 10.21873/cgp.20155
VO 16
IS 6
A1 HELENA LINARDOU
A1 VASSILIKI KOTOULA
A1 GEORGE KOUVATSEAS
A1 GIANNIS MOUNTZIOS
A1 VASILIOS KARAVASILIS
A1 EPAMINONDAS SAMANTAS
A1 ANNA KALOGERA-FOUNTZILA
A1 DESPINA TELEVANTOU
A1 KYRIAKI PAPADOPOULOU
A1 XANTHIPI MAVROPOULOU
A1 EMILY DASKALAKI
A1 THOMAS ZARAMBOUKAS
A1 IOANNIS EFSTRATIOU
A1 SOFIA LAMPAKI
A1 GRIGORIOS RALLIS
A1 ELENI RES
A1 KONSTANTINOS N. SYRIGOS
A1 PARIS A. KOSMIDIS
A1 DIMITRIOS PECTASIDES
A1 GEORGE FOUNTZILAS
YR 2019
UL http://cgp.iiarjournals.org/content/16/6/531.abstract
AB Background/Aim: KRAS mutations are reported in 20-25% of non-small cell lung cancer (NSCLC) and their prognostic role is unclear. We studied KRAS and EGFR genotyping in Greek NSCLC patients. Patients and Methods: KRAS and EGFR genotypes were centrally evaluated in 421 NSCLC patients (diagnosed September 1998 -June 2013) and associated with clinicopathological parameters. Outcome comparisons were performed in 288 patients receiving first line treatment. Results: Most patients were male (78.6%), >60 years old (63.9%), current smokers (51.1%), with adenocarcinoma histology (63.9%). EGFR and KRAS mutations were found in 10.7% and 16.6% of all histologies, respectively, and in 14.9% and 21.9% of adenocarcinomas. At 4.5 years median follow-up, KRAS status was an independent negative prognostic factor for overall survival (OS, p=0.016). KRAS mutations conferred 80% increased risk of death in patients receiving first-line treatment (p=0.002). Conclusion: The presence of KRAS mutations is an independent negative prognosticator among Greek NSCLC patients and an independent response predictor to first line treatment.